These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 37036990)

  • 1. Blockade of trans PD-L1 interaction with CD80 augments antitumor immunity.
    Zhang Y; Song Q; Cassady K; Lee M; Tang H; Zheng M; Wang B; Schones DE; Fu YX; Riggs AD; Martin PJ; Feng R; Zeng D
    Proc Natl Acad Sci U S A; 2023 Apr; 120(16):e2205085120. PubMed ID: 37036990
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PD-L1:CD80 Cis-Heterodimer Triggers the Co-stimulatory Receptor CD28 While Repressing the Inhibitory PD-1 and CTLA-4 Pathways.
    Zhao Y; Lee CK; Lin CH; Gassen RB; Xu X; Huang Z; Xiao C; Bonorino C; Lu LF; Bui JD; Hui E
    Immunity; 2019 Dec; 51(6):1059-1073.e9. PubMed ID: 31757674
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treg-expressed CTLA-4 depletes CD80/CD86 by trogocytosis, releasing free PD-L1 on antigen-presenting cells.
    Tekguc M; Wing JB; Osaki M; Long J; Sakaguchi S
    Proc Natl Acad Sci U S A; 2021 Jul; 118(30):. PubMed ID: 34301886
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Restriction of PD-1 function by
    Sugiura D; Maruhashi T; Okazaki IM; Shimizu K; Maeda TK; Takemoto T; Okazaki T
    Science; 2019 May; 364(6440):558-566. PubMed ID: 31000591
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Programmed Death-Ligand 1 on Antigen-presenting Cells Facilitates the Induction of Antigen-specific Cytotoxic T Lymphocytes: Application to Adoptive T-Cell Immunotherapy.
    Goto T; Nishida T; Takagi E; Miyao K; Koyama D; Sakemura R; Hanajiri R; Watanabe K; Imahashi N; Terakura S; Murata M; Kiyoi H
    J Immunother; 2016 Oct; 39(8):306-15. PubMed ID: 27548033
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD80 Expressed by CD8
    Rollins MR; Gibbons Johnson RM
    J Immunol Res; 2017; 2017():7659462. PubMed ID: 29181416
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A soluble form of CD80 enhances antitumor immunity by neutralizing programmed death ligand-1 and simultaneously providing costimulation.
    Haile ST; Horn LA; Ostrand-Rosenberg S
    Cancer Immunol Res; 2014 Jul; 2(7):610-5. PubMed ID: 24819296
    [TBL] [Abstract][Full Text] [Related]  

  • 8. By Binding CD80 and CD86, the Vaccinia Virus M2 Protein Blocks Their Interactions with both CD28 and CTLA4 and Potentiates CD80 Binding to PD-L1.
    Kleinpeter P; Remy-Ziller C; Winter E; Gantzer M; Nourtier V; Kempf J; Hortelano J; Schmitt D; Schultz H; Geist M; Brua C; Hoffmann C; Schlesinger Y; Villeval D; Thioudellet C; Erbs P; Foloppe J; Silvestre N; Fend L; Quemeneur E; Marchand JB
    J Virol; 2019 Jun; 93(11):. PubMed ID: 30918073
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Soluble CD80 Protein Delays Tumor Growth and Promotes Tumor-Infiltrating Lymphocytes.
    Horn LA; Long TM; Atkinson R; Clements V; Ostrand-Rosenberg S
    Cancer Immunol Res; 2018 Jan; 6(1):59-68. PubMed ID: 29122838
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dendritic Cell-Targeted Nanoparticles Enhance T Cell Activation and Antitumor Immune Responses by Boosting Antigen Presentation and Blocking PD-L1 Pathways.
    Srivastava P; Rütter M; Antoniraj G; Ventura Y; David A
    ACS Appl Mater Interfaces; 2024 Oct; 16(40):53577-53590. PubMed ID: 39344665
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New expression of PD-L1 on activated CD4
    Mazerolles F
    Hum Immunol; 2024 Jul; 85(4):110831. PubMed ID: 38870593
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PD-1 agonism by anti-CD80 inhibits T cell activation and alleviates autoimmunity.
    Sugiura D; Okazaki IM; Maeda TK; Maruhashi T; Shimizu K; Arakaki R; Takemoto T; Ishimaru N; Okazaki T
    Nat Immunol; 2022 Mar; 23(3):399-410. PubMed ID: 35145298
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The CTLA-4 immune checkpoint protein regulates PD-L1:PD-1 interaction via transendocytosis of its ligand CD80.
    Kennedy A; Robinson MA; Hinze C; Waters E; Williams C; Halliday N; Dovedi S; Sansom DM
    EMBO J; 2023 Mar; 42(5):e111556. PubMed ID: 36727298
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PD-L1 enhances CNS inflammation and infarct volume following experimental stroke in mice in opposition to PD-1.
    Bodhankar S; Chen Y; Vandenbark AA; Murphy SJ; Offner H
    J Neuroinflammation; 2013 Sep; 10():111. PubMed ID: 24015822
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PD-L1 Binds to B7-1 Only
    Chaudhri A; Xiao Y; Klee AN; Wang X; Zhu B; Freeman GJ
    Cancer Immunol Res; 2018 Aug; 6(8):921-929. PubMed ID: 29871885
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The programmed death-1 immune-suppressive pathway: barrier to antitumor immunity.
    Ostrand-Rosenberg S; Horn LA; Haile ST
    J Immunol; 2014 Oct; 193(8):3835-41. PubMed ID: 25281753
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of the role of negative T cell costimulatory pathways in CD4 and CD8 T cell-mediated alloimmune responses in vivo.
    Ito T; Ueno T; Clarkson MR; Yuan X; Jurewicz MM; Yagita H; Azuma M; Sharpe AH; Auchincloss H; Sayegh MH; Najafian N
    J Immunol; 2005 Jun; 174(11):6648-56. PubMed ID: 15905503
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A missing PD-L1/PD-1 coinhibition regulates diabetes induction by preproinsulin-specific CD8 T-cells in an epitope-specific manner.
    Schuster C; Brosi H; Stifter K; Boehm BO; Schirmbeck R
    PLoS One; 2013; 8(8):e71746. PubMed ID: 23977133
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Macitentan improves antitumor immune responses by inhibiting the secretion of tumor-derived extracellular vesicle PD-L1.
    Lee CH; Bae JH; Choe EJ; Park JM; Park SS; Cho HJ; Song BJ; Baek MC
    Theranostics; 2022; 12(5):1971-1987. PubMed ID: 35265193
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rigid, bivalent CTLA-4 binding to CD80 is required to disrupt the cis CD80/PD-L1 interaction.
    Robinson MA; Kennedy A; Orozco CT; Chen HC; Waters E; Giovacchini D; Yeung K; Filer L; Hinze C; Lloyd C; Dovedi SJ; Sansom DM
    Cell Rep; 2024 Sep; 43(9):114768. PubMed ID: 39277860
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.